Skip to main content
You have permission to edit this article.
Edit
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

68.34 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Dec 1, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 29,198
Open 68.34
Bid (Size) 68.15 (2)
Ask (Size) 68.18 (23)
Prev. Close 68.34
Today's Range 68.34 - 68.34
52wk Range 52.65 - 71.70
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Optimism Building for Advancing Pancreatic Cancer Treatment Therapies
EQNX::TICKER_START (NASDAQ:ONCY),(NYSE:RCUS),(NASDAQ:AZN),(NYSE:BMY),(NYSE:ABBV) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures Product Safety
2 Stocks That Could Surprise Investors in 2023
Investing in safe healthcare stocks may be an underrated strategy to deploy. 
Via The Motley Fool

Performance

YTD
+17.20%
+17.20%
1 Month
+14.19%
+14.19%
3 Month
+10.60%
+10.60%
6 Month
+2.05%
+2.05%
1 Year
+24.53%
+24.53%

More News

Read More
Why Shares of Compugen Rose 16.5% on Wednesday
Via The Motley Fool
AstraZeneca PLC (AZN) Q3 2022 Earnings Call Transcript
Via The Motley Fool
Why AstraZeneca Stock Shot Higher Today
Via The Motley Fool
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
AstraZeneca Showcases Strength of Hematology Portfolio and Pipeline Across Multiple Hard-to-Treat Conditions at ASH 2022
From AstraZeneca
Via Business Wire
Analyst Says Coinbase 'A Waste Of Time', Taylor Swift's Concert Fiasco Under DOJ Probe, Shopify Clocks Record Black Friday Sales: Top Stories Monday, Nov. 28
Via Benzinga
AstraZeneca Bets On UK Listed Firm For Lung Diseases
Via Benzinga
C4X Discovery Holdings plc: C4XD signs exclusive global licence worth up to $402 million¹ with AstraZeneca for the development and commercialisation of NRF2 Activator programme
From C4X Discovery Holdings plc
Via Globe NewsWire
European Official Says COVID-19 Booster Uptake Disappointing In The Region
Via Benzinga
Mirati Therapeutics Surges As Big Pharma Reportedly Preps For A Buyout Battle
Via Investor's Business Daily
AstraZeneca Aims to Redefine Breast Cancer Care With New Data Across the Treatment Spectrum At SABCS 2022
From AstraZeneca
Via Business Wire
2 Breakout Growth Stocks to Buy for the Long Haul
Via The Motley Fool
2 Stocks to Buy Whether or Not a Recession Is Coming
Via The Motley Fool
Why Shares of Compugen Jumped 17.86% on Thursday
Via The Motley Fool
How Long Can This Top Stock Continue Defying the Bear Market?
Via The Motley Fool
Alexion, AstraZeneca Rare Disease, Completes Acquisition of LogicBio® Therapeutics
From Alexion, AstraZeneca Rare Disease
Via Business Wire
Don't Use These 5 Non-Cost Effective COVID Treatments Including Antivirals From Merck and Gilead, Britain's NICE Says
Via Benzinga
Third COVID-19 Booster or Fifth Dose Not Required Despite Surge In Cases, Australian Health Authorities Say
Via Benzinga
Amazon To $103? Plus Piper Sandler Predicts $300 For Illumina
Via Benzinga
European Medicines Agency's Advisory Committee Backs Approval Of AstraZeneca's Three Cancer Drugs
Via Benzinga
FDA Approves AstraZeneca's Imfinzi/Imjudo Chemo Combo For Late Stage Lung Cancer
Via Benzinga
IMFINZI and IMJUDO with chemotherapy approved in the US for patients with metastatic non-small cell lung cancer
From AstraZeneca
Via Business Wire
Repeat COVID-19 Infection Increases Risk Of Acute Outcomes, Long COVID Symptoms, Study Shows
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.